Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

psychiatric diseases

- PMLiVE

J&J expands neuroscience capabilities with $14.6bn Intra-Cellular acquisition

The deal gives the company access to a range of central nervous system disorder drugs

- PMLiVE

Boehringer gains access to Synaffix’s ADC technology through $1.3bn licensing deal

The Lonza company will provide access to its ADC technologies for an undisclosed number of targets

- PMLiVE

Novartis and Schrödinger to advance drug candidates in deal worth over $2.4bn

The companies will advance therapeutics for undisclosed targets in Novartis’ core areas

- PMLiVE

AbbVie to expand neuroscience pipeline with $1.4bn Aliada Therapeutics acquisition

The deal includes a candidate in phase 1 development for Alzheimer's disease

Bayer symbol

Bayer and NextRNA Therapeutics enter oncology partnership worth $547m

The companies will advance small molecule therapeutics against a new class of targets for cancer

- PMLiVE

Boehringer Ingelheim’s Spevigo recommended by CHMP for generalised pustular psoriasis

The chronic neutrophilic inflammatory disease can lead to severe complications, including multisystem organ failure

- PMLiVE

Boehringer Ingelheim expands immuno-oncology pipeline with $1.3bn Nerio acquisition

The deal gives the company access to a preclinical immune checkpoint inhibitor programme

- PMLiVE

Boehringer Ingelheim’s Metalyse recommended by NICE to treat stroke in adults

Ischaemic stroke is responsible for around 85% of all stroke cases in the UK

- PMLiVE

Boehringer Ingelheim and Brainomix enter fibrosing lung disease partnership

Pulmonary fibrosis, a chronic lung condition, affects up to 20 out of every 100,000 people worldwide

- PMLiVE

Takeda and Degron enter molecular glue degrader partnership worth over $1.2bn

The companies will focus on targets in oncology, neuroscience and inflammation

- PMLiVE

Boehringer Ingelheim and 3T announce second cancer immunotherapy partnership

The collaboration brings the potential milestone payments of the agreements to $538.5m

- PMLiVE

Boehringer Ingelheim and Ribo announce liver disease partnership worth over $2bn

More than 440 million people worldwide are estimated to live with the inflammatory liver disease NASH

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links